Phytotherapy for benign prostatic hyperplasia

Public Health Nutrition

Volumn 3, Issue 4 A, 2000, Pages 459-472

  Wilt, T J ^a   Ishani, A ^a   Rutks, I ^a   MacDonald, R ^a  

^a Minneapolis VA Center for Chronic Disease Outcomes Research   (United States)

Author keywords

Benign prostatic hyperplasia; Meta analysis; Phytotherapy; Randomized controlled trials; Systematic reviews

Indexed keywords

CURCUBITA PEPO EXTRACT; HYPOXIS ROOPERI EXTRACT; PLACEBO; PLANT EXTRACT; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SECALE CEREALE EXTRACT; UNCLASSIFIED DRUG; URTICA DIOICA EXTRACT;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; LONG TERM CARE; MEDICINAL PLANT; META ANALYSIS; NOCTURIA; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; URINARY TRACT DISEASE; URINE FLOW RATE;

HYPOXIS; PEPO; PRUNUS AFRICANA; PYGEUM; SABAL; SECALE CEREALE; SERENOA; SERENOA REPENS; URTICA DIOICA;

EID: 0034508803     PISSN: 13689800     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1368980000000549     Document Type: Review

References (66)

1. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review
2. Harmless herbs? A review of the recent literature
3. Plant extracts in benign prostatic hyperplasia
4. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: A demographic analysis of awareness and use at the University of Chicago
5. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH
6. Phytotherapy for treatment of benign prostatic hyperplasia: Case not proven
7. Rationale for systematic reviews
8. Conservative nonhormonal treatment of patients with benign prostatic hyperplasia
9. Growing use of medicinal botanicals forces assessment by drug regulators
10. Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients
11. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review
12. Confronto fra estratto di Serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica
13. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate
14. Treatment of benign prostatic hyperplasia with phytosterols
15. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients
16. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia
17. Permixon versus placebo; resultats d'une étude multicentrique
18. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after the exclusion of placebo responders
19. Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon)
20. Behandlung des benignen prostataadenoms und der chronischen prostatatitis
21. Extractum Sabal fructus bei benigner prostata-hyperplasie (BPH). Klinische prufung im stadium I und II
22. Terapia medica dell'adenoma prostatico: Confronto della efficacia dell'estratto di Serenoa repens (Permixon®) versus l'estratto di Pygeum Africanum e placebo. Valutazione in doppio cieco
23. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme
24. Wirksamkeit eines Sabal-Urtica-kombinationspräparats bei der behandlung der benignen prostatahyperplasie (BPH)
25. Serenoa repens vs. gestonorone caproato nel trattamento dell'ipertofia prostatica benigna: Studio randomizzato
26. The value of permixon in benign prostatic hypertrophy
27. Sperimentazione clinica controllata sulla bioequivalenza terapeutica e sulla tollerabilita dei prodotti a base di Serenoa repens in capsule da 160 mg o capsule rettali da 640 mg
28. Kombination aus sabal und Urticaestrakt vs. finasterid bei BPH (Stad. I bis II nach Alken); Vergleich der therapeutischen wirksamkeit in einer einjahrigen doppelblindstudie
29. Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco vs. placebo
30. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: A meta-analysis of randomized clinical trials
31. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
32. Randomised, placebo-controlled, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia
33. Conservative treatment of benign prostatic hyperplasia with high-dosage β-sitosterol (65 mg): Results of a placebo-controlled double-blind study
34. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia
35. A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia
36. Phytotherapy for the prostate
37. Antiprostatic hypertrophic action of Cernilton pollen-extract
38. Micturition activity of pollen extract: Contractile effects on bladder and inhibitory effects on urethral smooth muscle of mouse and pig
39. Effects of Cernilton pollen-extract on the urethral smooth muscle and diaphragmatic neuromuscular specimen
40. Konservative therapie der benignen prostata-hyperplasie (BPH) mit Cernilton®N: Ergebnisse einer plazebokontrollierten doppleblindstudie
41. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen-extract, Cernilton: A double-blind, placebo-controlled study
42. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia
43. Clinical evaluation of Cernilton on benign prostatic hypertrophy: A multiple center double-blind study with Paraprost
44. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: A review of 25 years of published experience
45. Efficacy of Pygeum africanum extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: Evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study
46. Non hormonal treatment of benign prostatic hypertrophy. Clinical evaluation of the active extract of Pygeum africanum
47. Standardized extract of Pygeum africanum in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo
48. Etude controlee de l'efficacite d'un traitemente medical sur des sujets consultant pour la premiere fois pour un adenome de la prostate
49. II Tadenan nella terapia dell'adenoma prostatico. Studio anatomo-clinico
50. A clinical and urodynamic study of Tadenan in the treatment of benign prostatic hypertrophy
51. Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma
52. Studio sull'efficacia e sulla tollerabilita del Tadenan 50 in pazienti affeti da ipertrofia prostatica
53. Terapia medica dell'ipertrofia prostatica. Sperimentazione clinica controllata
54. Valutazione clinica e morfo-funzionale del trattamento a doppio cieco con placebo. Tadenan 50 e Tadenan 50 associato a Farlutal nei pazienti con ipertrofia prostatica benigna
55. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: Double-blind comparison of two doses
56. Medical treatment of fibroadenomatous hypertrophy of the prostate with a new plant substance
57. Efficacia e tollerabilita del trattamento dell' adenoma prostatico con Tadenan 50
58. L'impegio del Tadenan nell'adenoma prostatico, Ricerca clinica controllata
59. Terapia medica dell'adenoma della prostata: Valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo
60. Therapie der benignen Prostatahyperplasie mit Bazoton liquidum
61. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia
62. Re: Saw palmetto for benign prostatic hyperplasia